Correcting a naming error is useful, but it does not establish a clinical dose. Online arguments about Epitalon often move from the valid point that it differs from epithalamin to an unsupported claim that a fixed conversion solves the problem.
Identity is necessary but not sufficient
The FDA assessment distinguishes Epitalon from the pineal extract and separately evaluates free-base and acetate material. It does not supply a universal potency ratio between an extract and a synthetic tetrapeptide.
The composition of an extract, its formulation and the route used in a study all matter. A claim that one ingredient is the active part of a mixture does not establish that every effect of the mixture can be reproduced by a proportional amount of that ingredient.
What a useful dose study would need
Researchers would need a defined preparation, a relevant population, measured exposure and outcomes, adverse-event collection and an appropriate comparison. A dose-response relationship in cultured cells does not provide those elements for human use.
Nor can a schedule be selected solely to fit the contents or cost of a vial. Financial convenience is not evidence of efficacy or safety.
A recurring number on forums may reflect copying from an earlier post rather than independent clinical confirmation. Repetition does not resolve the underlying evidence gap.
How to handle conflicting advice
Ask for the original human study and identify exactly what it tested. Separate a clinical outcome from a hormone or gene-expression measurement. Check whether the paper concerns the same material and route.
For a prescribed product, clarify instructions with the responsible clinician and pharmacist. For research-only Epitalon, this article provides no conversion, starting amount or cycle.
The honest answer may be that the available research does not establish a safe and effective personal regimen. That is more useful than choosing one side of an online dosing dispute and presenting its arithmetic as medical evidence.